[HTML][HTML] Mathematical modeling to study optimal allocation of vaccines against COVID-19 using an age-structured population

G González-Parra, MR Cogollo, AJ Arenas - Axioms, 2022 - mdpi.com
Axioms, 2022mdpi.com
Vaccination against the coronavirus disease 2019 (COVID-19) started in early December of
2020 in the USA. The efficacy of the vaccines vary depending on the SARS-CoV-2 variant.
Some countries have been able to deploy strong vaccination programs, and large
proportions of their populations have been fully vaccinated. In other countries, low
proportions of their populations have been vaccinated, due to different factors. For instance,
countries such as Afghanistan, Cameroon, Ghana, Haiti and Syria have less than 10% of …
Vaccination against the coronavirus disease 2019 (COVID-19) started in early December of 2020 in the USA. The efficacy of the vaccines vary depending on the SARS-CoV-2 variant. Some countries have been able to deploy strong vaccination programs, and large proportions of their populations have been fully vaccinated. In other countries, low proportions of their populations have been vaccinated, due to different factors. For instance, countries such as Afghanistan, Cameroon, Ghana, Haiti and Syria have less than 10% of their populations fully vaccinated at this time. Implementing an optimal vaccination program is a very complex process due to a variety of variables that affect the programs. Besides, science, policy and ethics are all involved in the determination of the main objectives of the vaccination program. We present two nonlinear mathematical models that allow us to gain insight into the optimal vaccination strategy under different situations, taking into account the case fatality rate and age-structure of the population. We study scenarios with different availabilities and efficacies of the vaccines. The results of this study show that for most scenarios, the optimal allocation of vaccines is to first give the doses to people in the 55+ age group. However, in some situations the optimal strategy is to first allocate vaccines to the 15–54 age group. This situation occurs whenever the SARS-CoV-2 transmission rate is relatively high and the people in the 55+ age group have a transmission rate 50% or less that of those in the 15–54 age group. This study and similar ones can provide scientific recommendations for countries where the proportion of vaccinated individuals is relatively small or for future pandemics.
MDPI